A global phase II randomized trial comparing oral taxane ModraDoc006/r to intravenous docetaxel in metastatic castration resistant prostate cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

A global phase II randomized trial comparing oral taxane ModraDoc006/r to intravenous docetaxel in metastatic castration resistant prostate cancer

Published:2024-05 Issue: Volume:202 Page:114007
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Vaishampayan Ulka N.,Keessen Marianne^ORCID,Dreicer Robert^ORCID,Heath Elisabeth I.,Buchler Tomas^ORCID,Árkosy Péter F.,Csöszi Tibor,Wiechno Pawel,Kopyltsov Evgeny,Orlov Sergey V.,Plekhanov Alexey,Smagina Maria,Varlamov Sergei,Shore Neal D.

Publisher

Elsevier BV

Reference33 articles.

1. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study;Berthold;J Clin Oncol,2008

2. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer;Tannock;N Engl J Med,2004

3. Real-world treatment patterns and overall survival among men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) in the US Medicare population;Freedland;Prostate Cancer Prostatic Dis,2023

4. Patient-reported preferences for oral versus intravenous administration for the treatment of cancer: A review of the literature;Eek;Patient Prefer Adherence,2016

5. Anticancer oral therapy: Emerging related issues;Banna;Cancer Treat Rev,2010

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP